Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-04-01 20:47:21 ET · period of report 2026-03-27 · accession 0001079973-26-000440 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 20:47 | 2026-03-27 | STLN | Carter Robert Ross | CFO | A - Grant | $0.00 | -202.9K | 436.7K | -32% | $0 | |
| 2026-04-01 20:47 | 2026-03-27 | STLN | Carter Robert Ross | CFO | J - Other | $3.07 | -20.3K | 416.4K | -5% | -$62.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-27 | A | D | 202,914 | $0.00 | 436,725 | D | — | — | (F1) Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
| 2 | Common | Common Stock | 2026-03-27 | J | D | 20,320 | $3.07 | 416,405 | D | — | — | (F2) The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 31, 2026 |